Regeneron Pharmaceuticals
REGN
540 hedge funds and large institutions have $37.7B invested in Regeneron Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 179 increasing their positions, 208 reducing their positions, and 38 closing their positions.
100% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 38
14% more capital invested
Capital invested by funds: $32.9B → $37.7B (+$4.76B)
10% more funds holding in top 10
Funds holding in top 10: 20 → 22 (+2)
6% more funds holding
Funds holding: 508 → 540 (+32)
14% less repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 208
28% less call options, than puts
Call options by funds: $649M | Put options by funds: $901M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$846M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$181M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$169M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$107M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$85.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$386M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$140M |
| 3 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
-$95.6M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$84.3M |
| 5 |
Renaissance Technologies
New York
|
-$75.6M |
REGN Hedge Fund Activity: Q2 2015 in Review
540 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2015, worth a combined $37.7B — up 14% from $32.9B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new REGN positions and 38 closed out — a net gain of 38 holders — while 179 added to existing stakes and 208 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $846M. The largest seller was Sands Capital Management, cutting an estimated $386M.
- 540 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2015, up from 508 in Q1 2015.
- Funds reported $37.7B of Regeneron Pharmaceuticals stock for Q2 2015, up 14% quarter-over-quarter.
- 76 funds opened new Regeneron Pharmaceuticals positions in Q2 2015 and 38 closed out, a net change of +38 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2015 was Jennison Associates, an estimated $846M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2015 was Sands Capital Management, an estimated $386M sold.
Based on aggregated 13F filings for Q2 2015.